Holcim Ltd Unsponsored ADR (OTCMKTS:HCMLY – Get Free Report) has earned a consensus rating of “Buy” from the eleven brokerages that are covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $16.80.
Several brokerages have commented on HCMLY. BNP Paribas Exane upgraded shares of Holcim from a “neutral” rating to an “outperform” rating in a research report on Friday. Royal Bank Of Canada restated a “sector perform” rating on shares of Holcim in a research report on Monday, April 27th. The Goldman Sachs Group raised shares of Holcim from a “hold” rating to a “buy” rating in a research note on Thursday, April 9th. Citigroup raised shares of Holcim from a “hold” rating to a “strong-buy” rating in a research note on Thursday, March 5th. Finally, DZ Bank raised shares of Holcim from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 27th.
Read Our Latest Research Report on HCMLY
Holcim Price Performance
Holcim Company Profile
Holcim is a global building materials and solutions company headquartered in Switzerland that produces and supplies cement, aggregates, ready-mix concrete, asphalt and a range of prefabricated and construction-related products and services. Its offerings are aimed at construction and infrastructure markets, serving contractors, developers, municipalities and industrial customers with materials for residential, commercial and civil engineering projects.
The company traces its modern form to the 2015 combination of Swiss cement maker Holcim and France’s Lafarge, which created one of the world’s largest building-materials groups; the combined enterprise later simplified its name to Holcim.
Read More
- Five stocks we like better than Holcim
- 3 Retail Winners Using Cash Flow to Stay Ahead
- 3 Tech ETFs That Could Bounce Back After the AI Selloff
- 3 Penny Stocks Under $5 Backed by Real Revenue Growth
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Receive News & Ratings for Holcim Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Holcim and related companies with MarketBeat.com's FREE daily email newsletter.
